Lista de obras - Karin Berger - Dominio Público Uruguay

A retrospective observational single-centre study on the burden of immune thrombocytopenia (ITP).

artículo científico publicado en 2012

Antifungal treatment in haematological and oncological patients: Need for quality assessment in routine care.

artículo científico publicado en 2018

Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study

artículo científico publicado en 2006

Blood Product Supply in Germany: The Impact of Apheresis and Pooled Platelet Concentrates.

artículo científico publicado en 2016

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

scientific article published on 03 May 2018

Burden of oral mucositis in stem cell transplant patients-the patients' perspective.

artículo científico publicado en 2017

Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective

artículo científico publicado en 2016

Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial

scientific article published on 01 August 2000

Cost of bacterial vaginosis in pregnancy. Decision analysis and cost evaluation of a clinical study in Germany

scientific article published on 01 September 1999

Cost of illness and its predictors for Parkinson's disease in Germany

scientific article published on 01 January 2005

Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study.

artículo científico publicado en 2003

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

artículo científico publicado en 1998

Costs of illness and care in Parkinson's disease: an evaluation in six countries

scientific article published on 01 February 2011

Current Guidance for Brca Mutation Testing in Ovarian Cancer Patients.

artículo científico publicado en 2014

Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.

artículo científico publicado en 2015

Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis.

artículo científico publicado en 2008

Economic impact of community- and nosocomially acquired rotavirus gastroenteritis in Austria.

artículo científico publicado en 2001

Economics of prophylactic treatment.

artículo científico publicado en 2003

Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.

artículo científico publicado en 2002

Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany

artículo científico publicado en 2006

Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.

artículo científico publicado en 2011

Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias

artículo científico publicado en 2001

How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population.

artículo científico publicado en 2016

Influencing blood usage in Germany: what is optimal use?

artículo científico publicado en 2007

Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates

artículo científico

Linking medicine and economics: health economics and quality of life in haemophilia care.

artículo científico publicado en 2002

Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.

artículo científico publicado en 2011

Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates.

artículo científico

Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany

scientific article published on 31 July 2008

Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective

artículo científico publicado en 2016

Patient-reported measures of well-being in older multiple myeloma patients: use of secondary data source

scientific article published on 22 January 2020

Prospects for research in haemophilia with real-world data-An analysis of German registry and secondary data.

artículo científico publicado en 2018

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.

artículo científico publicado en 2007

Research in haemophilia B--approaching the request for high evidence levels in a rare disease

artículo científico

Socioeconomic evaluation in medicine in Europe. Core economic concepts.

artículo científico publicado en 1999

The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components

scientific article published on 23 April 2011

The economic burden of hepatitis B in Germany

scientific article published on 01 February 2000

The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches

artículo científico publicado en 2001

The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care--an observational analysis on non-small-cell lung cancer patients.

artículo científico publicado en 2013

The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers

artículo científico publicado en 2004

Treatment of children with severe haemophilia A and inhibitors: a health economic evaluation for Germany.

artículo científico publicado en 2013

Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany.

artículo científico publicado en 2009

Wishes and worries of haemophilia patients. A patient survey from Bavaria.

artículo científico publicado en 2017

[Combined hepatitis A/B immunization in children and adolescents. Economic evaluation of different immunization methods]

artículo científico publicado en 1999

[Cost effectiveness of captopril after myocardial infarct; comment]

scientific article published on 01 February 1996

[Cost structure of hepatitis B infection]

artículo científico publicado en 1997

[Cost-utility analysis of contrast-enhanced MR angiography with automated table-translation for diagnosis and therapy planning in patients with peripheral vascular disease].

artículo científico publicado en 2003

[Economic evaluation of various hepatitis B vaccination strategies in children and adolescents]

artículo científico publicado en 1998

[Health economic aspects of the use of blood and blood products]

scientific article published on 01 January 2006

[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]

artículo científico publicado en 1998

[Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients]

scientific article published on 01 January 2014

[The use of coagulation factors in hemophilia treatment]

artículo científico publicado en 2006

Lista de obras de Karin Berger

A retrospective observational single-centre study on the burden of immune thrombocytopenia (ITP).

Antifungal treatment in haematological and oncological patients: Need for quality assessment in routine care.

Assessing health-related quality of life in patients with Parkinson's disease in a prospective longitudinal study

Blood Product Supply in Germany: The Impact of Apheresis and Pooled Platelet Concentrates.

Burden of Oral Mucositis: A Systematic Review and Implications for Future Research

Burden of oral mucositis in stem cell transplant patients-the patients' perspective.

Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective

Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial

Cost of bacterial vaginosis in pregnancy. Decision analysis and cost evaluation of a clinical study in Germany

Cost of illness and its predictors for Parkinson's disease in Germany

Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study.

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

Costs of illness and care in Parkinson's disease: an evaluation in six countries

Current Guidance for Brca Mutation Testing in Ovarian Cancer Patients.

Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.

Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis.

Economic impact of community- and nosocomially acquired rotavirus gastroenteritis in Austria.

Economics of prophylactic treatment.

Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.

Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany

Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.

Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias

How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population.

Influencing blood usage in Germany: what is optimal use?

Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates

Linking medicine and economics: health economics and quality of life in haemophilia care.

Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.

Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates.

Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany

Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective

Patient-reported measures of well-being in older multiple myeloma patients: use of secondary data source

Prospects for research in haemophilia with real-world data-An analysis of German registry and secondary data.

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group.

Research in haemophilia B--approaching the request for high evidence levels in a rare disease

Socioeconomic evaluation in medicine in Europe. Core economic concepts.

The Wildbad Kreuth initiative: European current practices and recommendations for optimal use of blood components

The economic burden of hepatitis B in Germany

The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches

The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care--an observational analysis on non-small-cell lung cancer patients.

The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers

Treatment of children with severe haemophilia A and inhibitors: a health economic evaluation for Germany.

Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany.

Wishes and worries of haemophilia patients. A patient survey from Bavaria.

[Combined hepatitis A/B immunization in children and adolescents. Economic evaluation of different immunization methods]

[Cost effectiveness of captopril after myocardial infarct; comment]

[Cost structure of hepatitis B infection]

[Cost-utility analysis of contrast-enhanced MR angiography with automated table-translation for diagnosis and therapy planning in patients with peripheral vascular disease].

[Economic evaluation of various hepatitis B vaccination strategies in children and adolescents]

[Health economic aspects of the use of blood and blood products]

[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]

[Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients]

[The use of coagulation factors in hemophilia treatment]